Etizolam (also known as Etilaam, Etizola, Sedekopan, Etizest, Pasaden or Depas) is a thienodiazepine derivative which is a benzodiazepine analog.
The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring and triazole ring has been fused, making the drug a thienotriazolodiazepine.
It possesses amnesic,anxiolytic, anticonvulsant,hypnotic, sedative and skeletal muscle relaxant properties.
Etizolam, a thienodiazepine derivative, is absorbed fairly rapidly, with peak plasma levels achieved between 30 minutes and 2 hours. It has a mean elimination half life of about 3.5 hours.
In a study that compared the effectiveness of etizolam, alprazolam, and bromazepam for the treatment of generalized anxiety disorder, all three drugs retained their effectiveness over 2 weeks, but etizolam became more effective from 2 weeks to 4 weeks, a type of reverse tolerance.
Etizolam is sold for research purposes only and is not be utilized for any other purposes.